John M. L. Ebos Genitourinary Section, Department of Medicine Roswell Park Cancer Institute Biography Publications Institution JoVE Articles John M. L. Ebos has not added a biography. If you are John M. L. Ebos and would like to personalize this page please email our Author Liaison for assistance. Publications Preclinical Recapitulation of Antiangiogenic Drug Clinical Efficacies Using Models of Early or Late Stage Breast Cancer Metastatis Breast (Edinburgh, Scotland). Aug, 2013 | Pubmed ID: 24074794 Mind the Gap: Potential for Rebounds During Antiangiogenic Treatment Breaks Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2012 | Pubmed ID: 22679177 Antiangiogenic Therapy: Impact on Invasion, Disease Progression, and Metastasis Nature Reviews. Clinical Oncology. Apr, 2011 | Pubmed ID: 21364524 Peering into the Aftermath: The Inhospitable Host? Nature Medicine. Oct, 2010 | Pubmed ID: 20930748 Tumor and Host-mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2009 | Pubmed ID: 19671869 Dose-dependent Increases in Circulating TGF-alpha and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2009 | Pubmed ID: 19276250 Accelerated Metastasis After Short-term Treatment with a Potent Inhibitor of Tumor Angiogenesis Cancer Cell. Mar, 2009 | Pubmed ID: 19249681 Vascular Endothelial Growth Factor-mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels As a Surrogate Biomarker for Tumor Growth Cancer Research. Jan, 2008 | Pubmed ID: 18199548 Multiple Circulating Proangiogenic Factors Induced by Sunitinib Malate Are Tumor-independent and Correlate with Antitumor Efficacy Proceedings of the National Academy of Sciences of the United States of America. Oct, 2007 | Pubmed ID: 17942672 Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose Current Cancer Drug Targets. Nov, 2005 | Pubmed ID: 16305351 Down-regulation of DNA Mismatch Repair Proteins in Human and Murine Tumor Spheroids: Implications for Multicellular Resistance to Alkylating Agents Molecular Cancer Therapeutics. Oct, 2005 | Pubmed ID: 16227397 Increased Plasma Vascular Endothelial Growth Factor (VEGF) As a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Research. Sep, 2004 | Pubmed ID: 15374976 A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Molecular Cancer Research : MCR. Jun, 2004 | Pubmed ID: 15235107 Dok-R Binds C-Abl and Regulates Abl Kinase Activity and Mediates Cytoskeletal Reorganization The Journal of Biological Chemistry. Aug, 2003 | Pubmed ID: 12777393 Imatinib Mesylate (STI-571) Reduces Bcr-Abl-mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia Molecular Cancer Research : MCR. Dec, 2002 | Pubmed ID: 12496355 Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy Amanda Tracz1, Michalis Mastri1, Christina R. Lee2, Roberto Pili1, John M. L. Ebos1 1Genitourinary Section, Department of Medicine, Roswell Park Cancer Institute, 2Biological Sciences Platform, Sunnybrook Research Institute JoVE 51485 Médecine
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy Amanda Tracz1, Michalis Mastri1, Christina R. Lee2, Roberto Pili1, John M. L. Ebos1 1Genitourinary Section, Department of Medicine, Roswell Park Cancer Institute, 2Biological Sciences Platform, Sunnybrook Research Institute JoVE 51485 Médecine